Malignancy Clinical Trials in Edinburgh
10 recruitingEdinburgh, United Kingdom
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
Advanced Solid Malignancy
Grey Wolf Therapeutics300 enrolled29 locationsNCT06923761
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaHaematological Malignancy
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaOvarian NeoplasmsColorectal Neoplasms+3 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Haematological MalignancySolid Tumour
Cancer Research UK825 enrolled27 locationsNCT05722886
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
MalignancyMelanomaCancer+7 more
Cancer Research UK30 enrolled27 locationsNCT05770102